Skip to main content
Clinical Trials/DRKS00007621
DRKS00007621
Not yet recruiting
Not Applicable

Pregnancy outcome after first-trimester exposure to metformin: the experience of the Berlin institute for clinical teratology and drug risk assessment in pregnancy

Pharmakovigilanz- und Beratungszentrum für EmbryonaltoxikologieCharité - Universitätsmedizin Berlin0 sites1,500 target enrollmentAugust 27, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
congenital malformations/spontaneous abortions after intrauterine metformin exposure
Sponsor
Pharmakovigilanz- und Beratungszentrum für EmbryonaltoxikologieCharité - Universitätsmedizin Berlin
Enrollment
1500
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 27, 2015
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Sponsor
Pharmakovigilanz- und Beratungszentrum für EmbryonaltoxikologieCharité - Universitätsmedizin Berlin

Eligibility Criteria

Inclusion Criteria

  • Both cohorts: prospectively ascertained pregnancies, i.e. outcome of pregnancy is unknown at the time of contact to the study centre; study cohort: metformin exposure during the first trimester of pregnancy; control cohort: control group without metformin therapy

Exclusion Criteria

  • malignancies, exposure to established teratogens (lenalidomide, carbamazepine, methotrexate, mycophenolate, phenobarbital, phenprocoumon, phenytoin, retinoids (acitretin, adapalen, isotretinoin, tazaroten, tretinoin), thalidomide, topiramate, warfarin) or fetotoxicants (angiotensin\-converting enzyme (ACE)\-inhibitors and angiotensin II receptor antagonists) after the first trimester; valproaic acid\-exposed pregnancies will be evaluated separately (patients may be prone to PCOS)

Outcomes

Primary Outcomes

Not specified

Similar Trials